Cholesteryl butanoate is an ester formed from cholesterol and butanoic acid. It is a white crystalline solid that is insoluble in water but soluble in organic solvents. Cholesteryl butanoate has been studied for its potential use in the treatment of hypercholesterolemia, a condition characterized by high levels of cholesterol in the blood. Studies have shown that cholesteryl butanoate can lower cholesterol levels by inhibiting the absorption of cholesterol from the gut. However, further research is needed to determine the safety and efficacy of cholesteryl butanoate as a treatment for hypercholesterolemia.'
cholesteryl butanoate: RN given for (3beta)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 101741 |
| SCHEMBL ID | 161977 |
| MeSH ID | M0243421 |
| Synonym |
|---|
| 521-13-1 |
| cholesteryl butyrate |
| cholest-5-en-3-ol (3.beta.)-, butanoate |
| AKOS015839529 |
| cholesteryl butanoate |
| butyric acid cholesterol ester |
| cholesterol butyrate |
| [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] butanoate |
| einecs 208-304-7 |
| unii-50qa4ycp7f |
| cholest-5-en-3-ol (3beta)-, butanoate |
| 50qa4ycp7f , |
| cholest-5-en-3-ol (3beta)-, 3-butanoate |
| cholest-5-en-3beta-ol butyrate |
| 3.beta.-hydroxy-5-cholestene 3-butyrate |
| cholesterol n-butyrate |
| cholesteryl butyrate [inci] |
| cholesterol 3-butyrate |
| cholesteryl n-butyrate |
| butyric acid, cholesteryl ester |
| SCHEMBL161977 |
| W-105851 |
| 3.beta.-butanoyloxycholest-5-ene |
| 5-cholesten-3.beta.-ol butyrate |
| CKDZWMVGDHGMFR-GTPODGLVSA-N |
| n-butyric acid cholesterol ester |
| mfcd00021144 |
| AS-57753 |
| D95327 |
| cholest-5-en-3-beta-yl butanoate |
| 3beta-hydroxy-5-cholestene 3-butyrate |
| cholesteryln-butyrate |
| Q27260812 |
| CS-W013838 |
| DTXSID101341216 |
| HY-W013122 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cholesteryl butanoate has a complex crystal structure that differs from those of the three main structure type for cholesteryl esters. " | ( Crystal structure of cholesteryl butanoate at 123 K. Craven, BM; Han, GW; Langs, DA, 1994) | 2.05 |
| "Cholesteryl butanoate has a complex crystal structure that differs from those of the three main structure type for cholesteryl esters. " | ( Crystal structure of cholesteryl butanoate at 123 K. Craven, BM; Han, GW; Langs, DA, 1994) | 2.05 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.55) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (14.29%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||